Multiple Ascending Dose Evaluation of LY4256984 in Patients with Sporadic Amyotrophic Lateral Sclerosis

The primary objective of this study is to evaluate the safety and tolerability of **LY4256984** in participants with **Sporadic Amyotrophic Lateral Sclerosis** (ALS). This is clinically relevant as ALS is a progressive neurodegenerative disease with limited treatment options, and understanding the safety profile of new therapeutic agents is crucial for developing effective interventions. No secondary objectives are provided in the available data.

The clinical trial involves a total of **12 participants** diagnosed with **Sporadic Amyotrophic Lateral Sclerosis**. The study population includes both male and female subjects, with an age range spanning from adults to the elderly. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided. The general health status of the participants is not detailed, nor are any lifestyle considerations such as diet, physical activity, or habits. The sponsor has not disclosed further information regarding the selection process or additional demographic details.

The clinical trial is designed to evaluate the safety and efficacy of a new investigational product in participants diagnosed with **Sporadic Amyotrophic Lateral Sclerosis**. This study is a Phase 1 trial, which is typically the first stage of testing in human subjects and focuses on assessing the safety profile of the investigational product. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know who is receiving the investigational product or the placebo, thereby minimizing bias and ensuring the reliability of the results. The estimated duration of the trial is approximately two years, with recruitment expected to commence on September 15, 2025, and the study anticipated to conclude by July 26, 2027.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a comprehensive assessment, including medical history review and necessary diagnostic tests. Following successful screening, participants will be enrolled in the study and randomly assigned to receive either the investigational product or a placebo. Throughout the trial, participants will attend regular follow-up visits, which will include monitoring for adverse events, assessment of disease progression, and evaluation of the investigational product's pharmacokinetics and pharmacodynamics. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather data on the long-term effects of the treatment.

The expected length of participant involvement in the study is approximately two years, aligning with the overall trial duration. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, withdrawal of consent by the participant, or any other medical or ethical reasons deemed appropriate by the study investigators. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an initial investigation into the safety and potential efficacy of the intervention. The estimated recruitment start date is September 15, 2025, with an anticipated end date of July 26, 2027. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often focus on safety and pharmacokinetics, with preliminary efficacy assessments potentially included. The trial will likely involve regular assessments at predetermined intervals to monitor the intervention's impact on the condition under study. Data collection and analysis will adhere to rigorous scientific standards to ensure the reliability and validity of the findings. The trial's design will incorporate appropriate tools and instruments to measure relevant clinical outcomes, although specific instruments are not mentioned. The results will contribute to understanding the intervention's potential benefits and inform subsequent trial phases.